Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria.

Autor:	Odeigah LO; Department of Family Medicine, College of Health Science University of Ilorin, Ilorin, Kwara State, Nigeria., Mutalub YB; Department of Clinical Pharmacology and Therapeutics, College of Medical Sciences, Abubakar Tafawa Balewa University, Bauchi, Nigeria.; Department of Family Medicine Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria., Agede OA; Department of Pharmacology and Therapeutics University of Ilorin, Ilorin, Nigeria., Obalowu IA; Department of Family Medicine, General Hospital Ilorin, Ilorin, Kwara State, Nigeria., Aiyetoro S; Department of Pharmacy and Zonal Pharmacovigilance Center, University of Ilorin Teaching Hospital, Ilorin, Nigeria., Jimoh GAA; Department of Obstetrics and Gynaecology, University of Ilorin, Ilorin, Nigeria.
Jazyk:	angličtina
Zdroj:	PLOS global public health [PLOS Glob Public Health] 2022 Aug 15; Vol. 2 (8), pp. e0000835. Date of Electronic Publication: 2022 Aug 15 (Print Publication: 2022).
DOI:	10.1371/journal.pgph.0000835
Abstrakt:	Safe and effective vaccination remains the mainstay of control of COVID-19 because there is still no universally recommended treatment. This strategy is however being threatened by vaccine hesitancy and resistance due to fear of adverse events and safety concerns. It is, therefore, necessary to study post-vaccination adverse events (AE) in various populations and geographical areas. The objective of this study was to analyze the adverse events following COVID-19 vaccination in five major immunization centers of Kwara State Nigeria. A retrospective descriptive study of the adverse events following AstraZeneca COVID-19 vaccination that were reported from five immunization centers of Kwara State, North-central Nigeria from March to July 2021 was carried out. Statistical Package for Social Science version 26 was used for analysis. Adverse event classification and severity were compared based on age, gender, and time to onset of adverse event and vaccine dose type using the Chi-square test. The incidence of COVID-19 vaccine AE was 1.6%. There was female predominance (51.6%) and a mean age of 41.6±13.7 years. Most of the AE (95.8%) were systemic and mild (81.1%) without a requirement for any therapeutic intervention. Fatal outcome was not reported in any of the AE and the time to outcome of AE was 2 days in most cases (45.3%). No significant association was found between the variables studied and the adverse event type and severity. The low incidence and mild nature of adverse events reported in this study will add to the body of knowledge regarding vaccine adverse events and may eventually impact vaccine uptake. Competing Interests: The authors have declared that no competing interests exist. (Copyright: © 2022 Odeigah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu